The Effect of JAK1/2 Inhibitors on HIV Reservoir Using Primary Lymphoid Cell Model of HIV Latency.

CD4-Positive T-Lymphocytes / drug effects Gene Expression Profiling HIV Infections / immunology HIV-1 / drug effects Humans Immunophenotyping Janus Kinase 1 / antagonists & inhibitors Janus Kinase 2 / antagonists & inhibitors Janus Kinase Inhibitors / pharmacology Lymphocyte Activation / immunology Palatine Tonsil STAT Transcription Factors / metabolism Signal Transduction / drug effects Single-Cell Analysis Transcriptome Virus Activation / drug effects Virus Latency / drug effects Virus Replication / drug effects
HIV JAK-STAT signaling pathway LRA (latency reversing agent) latency scRNAseq tonsil

Journal

Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960

Informations de publication

Date de publication:
2021
Historique:
received: 04 06 2021
accepted: 13 08 2021
entrez: 17 9 2021
pubmed: 18 9 2021
medline: 22 12 2021
Statut: epublish

Résumé

HIV eradication is hindered by the existence of latent HIV reservoirs in CD4

Identifiants

DOI: 10.3389/fimmu.2021.720697 PMID: 34531866 PMC: PMC8438319
pubmed: 34531866
doi: 10.3389/fimmu.2021.720697
pmc: PMC8438319
doi:

Substances chimiques

Janus Kinase Inhibitors 0
STAT Transcription Factors 0
JAK1 protein, human EC 2.7.10.2
JAK2 protein, human EC 2.7.10.2
Janus Kinase 1 EC 2.7.10.2
Janus Kinase 2 EC 2.7.10.2

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

720697

Subventions

Organisme : NIAID NIH HHS
ID : P30 AI073961
Pays : United States
Organisme : NIAID NIH HHS
ID : P30 AI050409
Pays : United States

Informations de copyright

Copyright © 2021 de Armas, Gavegnano, Pallikkuth, Rinaldi, Pan, Battivelli, Verdin, Younis, Pahwa, Williams, Schinazi and Pahwa.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Cytokine. 2019 Aug;120:273-281
pubmed: 30910260
Immunity. 2018 Jun 19;48(6):1183-1194.e5
pubmed: 29802019
Clin Infect Dis. 2021 Mar 06;:
pubmed: 33693561
PLoS Pathog. 2015 Jun 11;11(6):e1004955
pubmed: 26067822
J Leukoc Biol. 2006 Nov;80(5):1145-55
pubmed: 16943383
Front Microbiol. 2020 Mar 04;11:297
pubmed: 32194526
Nat Med. 2020 Sep;26(9):1339-1350
pubmed: 32895573
J Neuroinflammation. 2019 Sep 27;16(1):182
pubmed: 31561750
Nat Med. 2016 Jul;22(7):754-61
pubmed: 27239760
J Clin Invest. 2018 Jul 2;128(7):3171-3185
pubmed: 29911996
J Virol. 2004 Sep;78(17):9458-73
pubmed: 15308739
J Infect Dis. 2013 Sep;208(6):884-91
pubmed: 23801609
Cell Host Microbe. 2015 Oct 14;18(4):463-70
pubmed: 26468749
PLoS Pathog. 2019 Mar 21;15(3):e1007311
pubmed: 30897187
Nature. 2017 Mar 23;543(7646):564-567
pubmed: 28297712
Elife. 2018 May 01;7:
pubmed: 29714165
J Immunol. 2008 Jul 1;181(1):557-65
pubmed: 18566422
Sci Transl Med. 2020 Mar 4;12(533):
pubmed: 32132218
J Virol. 2010 Jul;84(13):6425-37
pubmed: 20410271
J Infect Dis. 2017 Feb 15;215(4):614-622
pubmed: 28007920
J Int AIDS Soc. 2019 Dec;22(12):e25425
pubmed: 31855322
Pathog Immun. 2016 Spring;1(1):68-106
pubmed: 27430032
J Acquir Immune Defic Syndr. 2019 Dec 15;82(5):503-513
pubmed: 31714430
J Virol. 2021 Jan 13;:
pubmed: 33441346
AIDS. 2008 Sep;22 Suppl 3:S13-8
pubmed: 18845917
Nat Commun. 2019 Oct 18;10(1):4739
pubmed: 31628331
Proc Natl Acad Sci U S A. 1991 Nov 1;88(21):9838-42
pubmed: 1682922
Nat Med. 2020 Apr;26(4):519-528
pubmed: 32284611
PLoS Pathog. 2020 Apr 30;16(4):e1008450
pubmed: 32353080
EBioMedicine. 2016 Jun;8:248-264
pubmed: 27428435
Cell Rep. 2017 Jul 25;20(4):984-998
pubmed: 28746881
Nat Commun. 2018 Dec 21;9(1):5429
pubmed: 30575753
AIDS. 2019 Feb 1;33(2):199-209
pubmed: 30562171
Pathog Immun. 2017;2(2):179-192
pubmed: 28752134
Front Immunol. 2019 Sep 20;10:2251
pubmed: 31616425
Nat Med. 2009 Aug;15(8):893-900
pubmed: 19543283
PLoS Pathog. 2016 Jul 14;12(7):e1005761
pubmed: 27415008
Nat Med. 2017 May;23(5):638-643
pubmed: 28414330
J Clin Invest. 2016 Jul 1;126(7):2745-56
pubmed: 27322062
J Exp Med. 2013 Jan 14;210(1):143-56
pubmed: 23254284
Science. 1997 Nov 14;278(5341):1295-300
pubmed: 9360927
Cell Rep. 2018 Oct 2;25(1):107-117.e3
pubmed: 30282021
Nat Med. 2017 Nov;23(11):1271-1276
pubmed: 28967921
PLoS Pathog. 2012;8(7):e1002818
pubmed: 22911005
Proc Natl Acad Sci U S A. 2010 Sep 28;107(39):16934-9
pubmed: 20837531
Virology. 2013 Nov;446(1-2):283-92
pubmed: 24074592
Blood. 2009 Jan 1;113(1):58-65
pubmed: 18849485
Sci Immunol. 2018 Jun 1;3(24):
pubmed: 29858286
Nat Med. 2018 Sep;24(9):1430-1440
pubmed: 30082858
Blood. 2007 Dec 15;110(13):4161-4
pubmed: 17881634
Cell. 2013 Oct 24;155(3):540-51
pubmed: 24243014
AIDS Res Hum Retroviruses. 2019 Nov/Dec;35(11-12):1112-1122
pubmed: 31578868
Sci Transl Med. 2017 Jan 18;9(373):
pubmed: 28100833
Cell Host Microbe. 2016 Dec 14;20(6):785-797
pubmed: 27978436
PLoS Pathog. 2017 Dec 21;13(12):e1006740
pubmed: 29267399
Nature. 2019 Feb;566(7742):120-125
pubmed: 30700913
Cell Rep. 2018 Apr 24;23(4):942-950
pubmed: 29694901
Elife. 2020 Sep 29;9:
pubmed: 32990219
PLoS Pathog. 2013 Feb;9(2):e1003174
pubmed: 23459007
PLoS Biol. 2005 Feb;3(2):e41
pubmed: 15719057
J Immunol. 2017 Mar 1;198(5):1995-2005
pubmed: 28130496
J Virol. 2015 Dec 16;90(6):2718-28
pubmed: 26676775
Front Immunol. 2017 Nov 30;8:1698
pubmed: 29250073
PLoS Pathog. 2018 Feb 22;14(2):e1006856
pubmed: 29470552
J Clin Invest. 2020 Apr 1;130(4):1699-1712
pubmed: 31910162
Nat Commun. 2021 Mar 5;12(1):1474
pubmed: 33674572
Nat Med. 2015 Feb;21(2):132-9
pubmed: 25599132
Proc Natl Acad Sci U S A. 2008 Mar 11;105(10):3879-84
pubmed: 18332425

Auteurs

Lesley R de Armas (LR)

Department of Microbiology and Immunology, University of Miami Miller School of Medicine, Miami, FL, United States.

Christina Gavegnano (C)

Department of Pathology and Experimental Medicine, Emory University and Children's Healthcare of Atlanta, Atlanta, GA, United States.
Department of Pharmacology and Chemical Biology, Emory University and Children's Healthcare of Atlanta, Atlanta, GA, United States.
Center for AIDS Research, Department of Pediatrics, Emory University and Children's Healthcare of Atlanta, Atlanta, GA, United States.

Suresh Pallikkuth (S)

Department of Microbiology and Immunology, University of Miami Miller School of Medicine, Miami, FL, United States.

Stefano Rinaldi (S)

Department of Microbiology and Immunology, University of Miami Miller School of Medicine, Miami, FL, United States.

Li Pan (L)

Department of Microbiology and Immunology, University of Miami Miller School of Medicine, Miami, FL, United States.

Emilie Battivelli (E)

Gladstone Institute of Virology and Immunology, Gladstone Institutes, San Francisco, CA, United States.
Department of Medicine, University of California San Francisco, San Francisco, CA, United States.
Buck Institute for Research on Aging, Novato, CA, United States.

Eric Verdin (E)

Gladstone Institute of Virology and Immunology, Gladstone Institutes, San Francisco, CA, United States.
Department of Medicine, University of California San Francisco, San Francisco, CA, United States.
Buck Institute for Research on Aging, Novato, CA, United States.

Ramzi T Younis (RT)

Department of Otolaryngology, University of Miami Miller School of Medicine, Miami, FL, United States.

Rajendra Pahwa (R)

Department of Microbiology and Immunology, University of Miami Miller School of Medicine, Miami, FL, United States.

Siôn L Williams (SL)

Department of Neurology, University of Miami Miller School of Medicine, Miami, FL, United States.

Raymond F Schinazi (RF)

Center for AIDS Research, Department of Pediatrics, Emory University and Children's Healthcare of Atlanta, Atlanta, GA, United States.

Savita Pahwa (S)

Department of Microbiology and Immunology, University of Miami Miller School of Medicine, Miami, FL, United States.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Systèmes sanguin et immunitaire › Système immunitaire › Leucocytes › Agranulocytes › Lymphocytes › Lymphocytes T › Lymphocytes T CD4+ › The Effect of JAK1/2 Inhibitors on HIV...
questionsmedicales.fr › Techniques d'investigation › Techniques génétiques › Analyse de profil d'expression de gènes › The Effect of JAK1/2 Inhibitors on HIV...
questionsmedicales.fr › Maladies du système immunitaire › Déficits immunitaires › Infections à VIH › The Effect of JAK1/2 Inhibitors on HIV...
questionsmedicales.fr › Virus › Virus à ARN › Retroviridae › Lentivirus › Lentivirus des primates › VIH (Virus de l'Immunodéficience Humaine) › VIH-1 (Virus de l'Immunodéficience Humaine de type 1) › The Effect of JAK1/2 Inhibitors on HIV...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › The Effect of JAK1/2 Inhibitors on HIV...
questionsmedicales.fr › Techniques d'investigation › Techniques immunologiques › Tests immunologiques › Immunophénotypage › The Effect of JAK1/2 Inhibitors on HIV...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines et peptides de signalisation intracellulaire › Protein-tyrosine kinases › Janus kinases › Janus kinase 1 › The Effect of JAK1/2 Inhibitors on HIV...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines tumorales › Protéines oncogènes › Protéines proto-oncogènes › Kinase Janus-2 › The Effect of JAK1/2 Inhibitors on HIV...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Mécanismes moléculaires de l'action pharmacologique › Antienzymes › Inhibiteurs de protéines kinases › Inhibiteurs des Janus kinases › The Effect of JAK1/2 Inhibitors on HIV...
questionsmedicales.fr › Phénomènes du système immunitaire › Activation des lymphocytes › The Effect of JAK1/2 Inhibitors on HIV...
questionsmedicales.fr › Systèmes sanguin et immunitaire › Système immunitaire › Système lymphatique › Tissu lymphoïde › Tonsille palatine › The Effect of JAK1/2 Inhibitors on HIV...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Facteurs de transcription › Facteurs de transcription STAT › The Effect of JAK1/2 Inhibitors on HIV...
questionsmedicales.fr › Phénomènes physiologiques cellulaires › Transduction du signal › The Effect of JAK1/2 Inhibitors on HIV...
questionsmedicales.fr › Techniques d'investigation › Techniques cytologiques › Analyse sur cellule unique › The Effect of JAK1/2 Inhibitors on HIV...
questionsmedicales.fr › Phénomènes génétiques › Structures génétiques › Transcriptome › The Effect of JAK1/2 Inhibitors on HIV...
questionsmedicales.fr › Phénomènes microbiologiques › Phénomènes physiologiques viraux › Réplication virale › Activation virale › The Effect of JAK1/2 Inhibitors on HIV...
questionsmedicales.fr › Phénomènes microbiologiques › Phénomènes physiologiques viraux › Latence virale › The Effect of JAK1/2 Inhibitors on HIV...
questionsmedicales.fr › Phénomènes microbiologiques › Phénomènes physiologiques viraux › Réplication virale › The Effect of JAK1/2 Inhibitors on HIV...